• Find people
• Intranet

Molecular cancer therapeutics Joan Albanell

Publications 2024 (33)

• Peressini M, García-Campelo R, Massuti B, Marti C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Cordoba JF, Diz MP, Isla D, Esteban E, Carcereny E, Vila L, Moreno-Vega A, Ros S, Moreno A, Garcia FJ, Huidobro G, Aguado C, Cebey-Lopez V, Valdivia J, Palmero R, Lianes P, Lopez-Brea M, Vidal OJ, Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce-Aix S, Nuñez-Buiza A, Ucero Á, Hernandez S, López-Ríos F, Conde E, Paz-Ares L^*, Zugazagoitia J^*. Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer. Clin Cancer Res 2024: (en Premsa).
• Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis-Soto L, Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM^*. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities. Clin Cancer Res 2024: (en Premsa).
• Hernández A, Rodríguez-Vida A, Cardona L, Qin M, Arpí O, Soria-Jiménez L, Menéndez S, Quimis F, Galindo M, Arriola E, Salido M, Juanpere N, Rojo F, Muntasell A, Albanell J, Rovira A, Bellmunt J^*. Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. Mol Oncol 2024: (en Premsa).
• Rodríguez-Chiaradia DA^*, Rodó A, Espina-Gonzalez C, Caballero-Rabasco MA, Ausin P, Sancho A, Preckler J, Admetllo M, Marco E, García J. Diagnosis and Management of Exercise-induced Laryngeal Obstruction (EILO): Initial Results of a Multidisciplinary Team. Arch Bronconeumol 2024: (en Premsa).
• Verlingue L, Italiano A, Prenen H, Guerra-Alia EM, Tosi D, Perets R, Lugowska I, Moiseyenko V, Gumus M, Arslan C, Lindsay CR, Deva S, Taus A, Oaknin A, Rottey S, Cicin I, Goksu SS, Smolin A, Roselló-Keränen S, Habigt C, Marbach D, Boetsch C, Dejardin D, Sleiman N, Evers S, Richard M, Ardeshir C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Dziadziuszko R^*. Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma. EBioMedicine 2024; 109: (en Premsa).
• Fernández-Nestosa MJ, Sanchez DF, Cañete-Portillo S, Alemany L, Clavero O, Lloveras B, Rodriguez I, Lobatti A, Urizar C, Munoz N, Quint W, de Sanjosé S, Bosch FX, Cubilla AL^*, HPV VVAP Study Group. Human Papillomavirus (HPV) Genotypes in Mixed Squamous Cell Carcinoma of the Penis: A Study of 101 Tumors. Int J Surg Pathol 2024: (en Premsa).
• Mirallas O^*, Martin-Cullell B, Navarro V, Vega KS, Recuero J, Gómez-Puerto D, López-Valbuena D, Salva de Torres C, Andurell L, Pedrola A, Berché R, Palmas F, Ucha JM, Villacampa G, Rezqallah A, Sanz-Beltran J, Bach R, Bueno S, Viaplana C, Molina G, Hernando-Calvo A, Aguilar-Company J, Roca M, Muñoz-Couselo E, Martínez-Martí A, Alonso A, Eremiev S, Macarulla T, Oaknin A, Saura C, Élez E, Felip E, Peñuelas Á, Burgos R, Gómez-Pardo P, Garralda E, Tabernero J, Serradell S, Servitja S, Paez D, Dienstmann R, Carles J. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study. Lancet Reg Health Eur . 2024; 46: 101063 (Acceptat).
• Cortés A, López-Miranda E, Fernandez-Ortega A, Carañana V, Servitja S, Urruticoechea A, Lema L, Marquez A, Lazaris A, Alcalá-López D, Mina L, Gener P, Rodríguez-Morató J, Antonarelli G, Llombart-Cussac A^*, Perez-Garcia J, Cortés J. Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study. Breast 2024; 78: 103834.
• de la Haba-Rodríguez J^*, Mínguez P, Rojo F, Martin M, Alba E, Servitja S, Prat A, Pérez-Fidalgo JA, Gavilá J, Morales C, Rodríguez-Lescure A, Herrero C, Peña-Enriquez R, Herranz J, Hernando C, Hernández-Blanquisett A, Guil-Luna S, Martinez MT, Blanch S, Caballero R, Martín N, Pollán M, Guerrero Á, Bermejo B. Gestational breast cancer: distinctive molecular and clinico-epidemiological features. J Mammary Gland Biol 2024; 29(1): 18.
• Calpe-Damians N^*, Wennberg-Capellades L, Ventura-Rosado A, Gonzalez-Engroba R, Enríquez-Pérez N, Vicario-Martos C, Roldos-Gales A, Guri T, Rafart-Aguado S, Ramírez-Ramon A, Llauradó-Serra M. Effectiveness and safety of a simple catheter securement device aimed at preventing catheter-associated urinary tract infection in intensive care unit patients: A randomized controlled trial. NURS CRIT CARE 2024; 29: 1788-1798.
• Vernet-Tomas M^*, Vazquez I, Olivares F, Lopez D, Yelamos J, Comerma L. Human Leukocyte Antigen Class I Expression and Natural Killer Cell Infiltration and Its Correlation with Prognostic Features in Luminal Breast Cancers. Breast Cancer 2024; 16: 657-666 (Acceptat).
• Arriola E, Jaal J, Edvardsen A, Silvoniemi M, Araújo A, Vikström A, Zairi E, Rodriguez-Mues MC, Roccato M, Schneider S, Ammann J^*. Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer. Oncologist. 2024; 29(4): e561-e569.
• Vaz-Batista M, Pérez-García JM, Cortez P, Garrigós L, Fernández-Abad M, Gion M, Martinez-Bueno A, Saavedra C, Teruel I, Fernandez-Ortega A, Servitja S, Ruiz-Borrego M, de la Haba-Rodríguez J, Martrat G, Pérez-Escuredo J, Alcalá-López D, Sampayo-Cordero M, Braga S, Cortés J^*, Llombart-Cussac A^*. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open 2024; 9(9): 103699.
• Arriola E^*, de Castro-Carpeño J, García-Campelo R, Bernárdez B, Bernabé R, Bruna J, Dómine M, Isla D, Juan-Vidal O, López-Fernández T, Nadal E, Rodríguez-Abreu D, Vares M, Asensio Ú, García LF, Felip E. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clin Drug Invest 2024; 44(8): 553-576.
• Seguí E, Torres JM, Auclin E, Casadevall D, Peiro-Carmona S, Aguilar-Company J, Garcia de Herreros M, Gorría T, Laguna JC, Rodriguez M, Gonzalez A, Epaillard N, Gavira J, Bolaño V, Tapia JC, Tagliamento M, Teixidó C, Arasanz H, Pilotto S, Lopez-Castro R, Mielgo-Rubio X, Urbano C, Recondo G, Diaz-Pavon M, Bluthgen MV, Minatta JN, Lupinacci L, Brasó F, Prat A, Vlagea A, Mezquita L^*. The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease. Cancers 2024; 16(17): 2974.
• Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil MJ, Ruiz-Borrego M, Gavilá J, Aguirre E, Schmid P, Marmé F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de-Dueñas E, Amillano K, Shimizu E, Sampayo M, Cortés J, Llombart-Cussac A^*. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer. Breast 2024; 76: 103761.
• Espina-Gonzalez C^*, Núñez-Batalla F, Mackers P, Sumarroca A, Cantón-Bascuas M, García J. Dysphonia and other voice alterations associated with COVID-19: Systematic review. Acta Otorrinolaringol Esp 2024; 75(4): 252-259.
• Martínez-Jáñez N, Bellet M, Manso-Sanchez LM, Carrasco FH, Torres AA, Morales S, Ortega PT, Gil VLO, Sampedro T, Conejero RA, Calvo-Martinez L, Galve-Calvo E, López R, Ayala de la Peña F, Lopez-Tarruella S, de Araguiz BAHF, Ruiz LB, Martos T, Chacon JI, Antón FM^*. First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-) breast cancer: The real-life study PALBOSPAIN. Breast Cancer Res Tr 2024; 206(2): 317-328.
• Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharpe J, Farid S, Rocha P, Arriola E, D'aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB^*. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. 2024; 19: 928-940.
• Gately L^*, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martínez-García M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). J Neuro-Oncol 2024; 168(2): 299-306.
• Campos-Mármol MC, Aguado M, Ramón y Cajal T, Gallardo A, Catasús L, Gonzalez A, Méndez JE, Lasa A, Arumí M, Gallego-Rubio O, Serra JB, Muñoz-Hernández F, von Deimling A, Kommoss FKF, Espinosa I^*. Non-C19MC-altered embryonal tumor with multilayered rosettes in a young woman with DICER1 syndrome: case report and review of the literature. Pathologica . 2024; 116(3): 170-175.
• Muñoz S^*, Serrano-Oviedo L, Martínez-García M, Pardo Y, Tares L, Gomez-Romero FJ, Garcimartín P. Spanish version of the short European Health Literacy Survey Questionnaire HLS-Q12: Transcultural adaptation and psychometric properties. PLoS One . 2024; 19(2): e0299736 (Acceptat).
• Torres-Esquius S, Llop-Guevara A, Gutierrez-Enriquez S, Romey M, Teulé À, Llort G, Herrero A, Sánchez-Henarejos P, Vallmajó A, González-Santiago S, Chirivella I, Cano JM, Graña B, Simonetti S, Díaz de Corcuera I, Ramón y Cajal T, Sanz J, Serrano S, Otero A, Churruca C, Sanchez-Heras AB, Servitja S, Guillén-Ponce C, Brunet J, Denkert C, Serra V, Balmaña J^*. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Netw Open 2024; 7(4): e247811.
• Conde E, Hernandez S, Rodriguez-Carrillo JL, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clavé S, Arriola E, Esteban-Rodriguez I, de Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, López-Vilaró L, Majem M, Paz-Ares L, López-Ríos F^*. RET Fusion Testing in Patients With NSCLC: The RETING Study. JTO Clin Res Rep . 2024; 5(4): 100653 (Acceptat).
• Bellosillo B, Ibáñez R, Roura E, Monfil L, Asensio-Puig L, Alvarez I, Muset M, Florencia Y, Paytubi S, de Andrés-Pablo A, Calvo S, Serrano L, Pavón MÁ, Lloveras B^*. Clinical Validation of the Vitro HPV Screening Assay for Its Use in Primary Cervical Cancer Screening. Cancers 2024; 16(7): 1322.
• Santana-Hernández S, Suárez J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera J, Menéndez S, Arpí O, Bermejo B, Martínez-Larrad MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A^*. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. J Exp Clin Canc Res 2024; 43(1): 10.
• Nicolau P, Maso P, Argudo N, JIMÉNEZ M, Martinez AI, Vazquez I, Comerma L, Vernet-Tomas M^*. P53 expression correlates with low axillary tumor burden in breast cancer. Breast Dis . 2024; 42(1): 429-435.
• Gately L^*, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Pérez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martínez-García M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma. J Neuro-Oncol 2024; 166(3): 407-415.
• Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA^*, Heymach JV^*. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 2024; 42(2): 225-237.
• Muñoz S, Martínez-García M, Serrano-Oviedo L^*, Gomez-Romero FJ, Sobrado AM, Cidoncha-Moreno MÁ, Riesgo-Martin J, Pedreira-Robles G, Garcimartín P. Impact of telenurse-led intervention in clinical trials on health literacy, empowerment, and health outcomes in patients with solid tumours: a pilot quasi-experimental study. BMC Nurs 2024; 23(1): 86.
  Cites:0
  Cites:0
• Recuero J^*, Masfarre-Pinto L, Navarro-Gorro N, Rocha P, Taus A, Arriola E. Non-bacterial thrombotic endocarditis in ROS1-rearranged lung cancer: a report of two cases. Transl Lung Cancer Res 2024; 13(1): 179-185.
• Nadal R, Valderrama BP, Bellmunt J^*. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol . 2024; 21(1): 8-27.
• Jiménez-Pulido I^*, Albert-Marí MA, Conde-Estevez D, San José-Ruiz B, Gil-Lemus MÁ, Cercós-Lletí AC, Esteban-Mensua MJ, Díaz-Carrasco MS. GEDEFO-SEFH management of antineoplastic extravasations survey results. J Oncol Pharm Pract 2024; 30(1): 67-77.